TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of 3 Months Daily Treatment With Selective Serotonin Reuptake Inhibitor (SSRI, Fluoxetine) on Motor Rehabilitation After Ischemic Stroke. FLAME Trial
Brief Summary: Recovery from stroke is a major process and, except for acute intravenous thrombolysis, no treatment able to enhance recovery has yet been validated. Some drugs may have a positive effect when combined with physical rehabilitation. Previous studies have shown a potential effect of catecholaminergic drugs on cerebral plasticity of stroke patients. In 2001, our group has demonstrated in a small group of stroke patients (n=8) that a single dose of fluoxetine (Selective Serotonin Reuptake Inhibitor - SSRI) improved motor performance and modulated cerebral plasticity. We conducted a phase IIb prospective, double-blind, randomized, placebo controlled study to assess the effect of a daily treatment with fluoxetin (20 mg) on motor performance in patients with mild to severe motor deficit after ischemic stroke.


Options:
A: Arm Label: Sham Stimulation; Type: SHAM_COMPARATOR; Interventions: Device: Transcranial Direct Current Stimulation | Arm Label: Active Stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: Transcranial Direct Current Stimulation | Intervention Type: DEVICE; Name: Transcranial Direct Current Stimulation; Assigned to Arm(s): Active Stimulation, Sham Stimulation
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Modified cognitive behavioral therapy plus problem-solving | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Intervention Type: BEHAVIORAL; Name: Modified cognitive behavioral therapy plus problem-solving; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluoxetine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: Dialogue-based psychosocial intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dialogue-based psychosocial rehabilitation | Arm Label: Usual care Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dialogue-based psychosocial rehabilitation; Assigned to Arm(s): Dialogue-based psychosocial intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of 3 Months Daily Treatment With Selective Serotonin Reuptake Inhibitor (SSRI, Fluoxetine) on Motor Rehabilitation After Ischemic Stroke. FLAME Trial
Brief Summary: Recovery from stroke is a major process and, except for acute intravenous thrombolysis, no treatment able to enhance recovery has yet been validated. Some drugs may have a positive effect when combined with physical rehabilitation. Previous studies have shown a potential effect of catecholaminergic drugs on cerebral plasticity of stroke patients. In 2001, our group has demonstrated in a small group of stroke patients (n=8) that a single dose of fluoxetine (Selective Serotonin Reuptake Inhibitor - SSRI) improved motor performance and modulated cerebral plasticity. We conducted a phase IIb prospective, double-blind, randomized, placebo controlled study to assess the effect of a daily treatment with fluoxetin (20 mg) on motor performance in patients with mild to severe motor deficit after ischemic stroke.


Options:
A: Arm Label: Selective Serotonin Reuptake Inhibitors; Type: ACTIVE_COMPARATOR; Interventions: Drug: Citalopram | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): Selective Serotonin Reuptake Inhibitors | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: sugar pill | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): escitalopram | Intervention Type: DRUG; Name: sugar pill; Assigned to Arm(s): placebo
C: Arm Label: 1 Problem Solving Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy | Arm Label: 2. Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): 1 Problem Solving Therapy | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 2. Escitalopram | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluoxetine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Initialization of Methadone in Primary Care; a Randomized Intervention Research for Preventing HCV Transmission Practices. ANRS Methaville
Brief Summary: The rapid scale up of opioid substitution treatment (OST) for drug users mainly achieved through the possibility of prescribing buprenorphine in primary care has been successful in reducing HIV prevalence among drug users but still inadequate for reducing the spread of HCV. To date, methadone in France can only be initialised in drug centres but GPs can prescribe methadone after stabilisation of dosages.

This study was born as an answer to a request from the French Minister of Health that supports the initialisation of methadone in primary care in order to improve coverage by OST (now 70%) in drug users.


Options:
A: Arm Label: Depot Naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Depot naltrexone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment as Usual (TAU) | Intervention Type: DRUG; Name: Depot naltrexone; Assigned to Arm(s): Depot Naltrexone | Intervention Type: OTHER; Name: Treatment as Usual (TAU); Assigned to Arm(s): Placebo
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Methadone | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): A, B
C: Intervention Type: DEVICE; Name: Interactive computer based health-risk survey before doctor's visit; Assigned to Arm(s): N/A
D: Arm Label: Extended-Release Naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Intervention Type: DRUG; Name: Extended-Release Naltrexone; Assigned to Arm(s): Extended-Release Naltrexone, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Initialization of Methadone in Primary Care; a Randomized Intervention Research for Preventing HCV Transmission Practices. ANRS Methaville
Brief Summary: The rapid scale up of opioid substitution treatment (OST) for drug users mainly achieved through the possibility of prescribing buprenorphine in primary care has been successful in reducing HIV prevalence among drug users but still inadequate for reducing the spread of HCV. To date, methadone in France can only be initialised in drug centres but GPs can prescribe methadone after stabilisation of dosages.

This study was born as an answer to a request from the French Minister of Health that supports the initialisation of methadone in primary care in order to improve coverage by OST (now 70%) in drug users.


Options:
A: Arm Label: Intramuscular naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vivitrol- Intramuscular naltrexone (depot-formulation) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vivitrol- Intramuscular naltrexone (depot-formulation); Assigned to Arm(s): Intramuscular naltrexone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Interim; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Interim | Arm Label: Comprehensive; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Comprehensive | Arm Label: Restored; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Restored | Intervention Type: BEHAVIORAL; Name: Interim; Assigned to Arm(s): Interim | Intervention Type: BEHAVIORAL; Name: Comprehensive; Assigned to Arm(s): Comprehensive | Intervention Type: BEHAVIORAL; Name: Restored; Assigned to Arm(s): Restored
C: Arm Label: TAU only; Type: ACTIVE_COMPARATOR; Interventions: Other: Intensive Outpatient Treatment | Arm Label: TMAC only; Type: EXPERIMENTAL; Interventions: Other: Adaptive telephone-based counseling | Arm Label: TMAC plus; Type: EXPERIMENTAL; Interventions: Other: Adaptive telephone-based counseling plus incentives | Intervention Type: OTHER; Name: Intensive Outpatient Treatment; Assigned to Arm(s): TAU only | Intervention Type: OTHER; Name: Adaptive telephone-based counseling; Assigned to Arm(s): TMAC only | Intervention Type: OTHER; Name: Adaptive telephone-based counseling plus incentives; Assigned to Arm(s): TMAC plus
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Methadone | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): A, B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Initialization of Methadone in Primary Care; a Randomized Intervention Research for Preventing HCV Transmission Practices. ANRS Methaville
Brief Summary: The rapid scale up of opioid substitution treatment (OST) for drug users mainly achieved through the possibility of prescribing buprenorphine in primary care has been successful in reducing HIV prevalence among drug users but still inadequate for reducing the spread of HCV. To date, methadone in France can only be initialised in drug centres but GPs can prescribe methadone after stabilisation of dosages.

This study was born as an answer to a request from the French Minister of Health that supports the initialisation of methadone in primary care in order to improve coverage by OST (now 70%) in drug users.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Methadone | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methadone | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): A, B
B: Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Peer Education Intervention; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Buprenorphine/naloxone; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Feasibility of Correcting Refractive Error From a Limited Inventory of Ready-made Spectacles: Wearer Retention, Vision Function, Quality of Life and Cost
Brief Summary: This research project will compare two methods of correcting refractive error (long or short-sightedness) with spectacle lenses. The primary outcome is the proportion of the population requiring spectacle correction who's needs are met through each scheme. Secondary outcomes are the cost effectiveness of these schemes and development of guidelines for identification of those amongst the population suitable for 'ready-made' spectacles.

There are two sites involved in this research. Those with uncorrected refractive error will be identified by their distance vision. Those who have impaired vision (at least 20/40) which improves with spectacles will be invited to participate in this research. Participants will be randomly allocated to one of two groups. The first group will receive spectacles with full correction in both eyes and the second group will receive spectacles from a limited inventory. The two schemes will be compared by how many people continue to use the spectacles, vision with the new spectacles, change in the level of visual functioning and quality of life after wearing new spectacles for one month. At the one month visit, if the spectacles provided are not useful, one new pair of custom spectacles will be dispensed.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Ready-made spectacles | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Spectacles | Intervention Type: DEVICE; Name: Ready-made spectacles; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Spectacles; Assigned to Arm(s): 2
B: Arm Label: Test lens C; Type: EXPERIMENTAL; Interventions: Device: 1 Day Acuvue Moist | Arm Label: Test lens A; Type: ACTIVE_COMPARATOR; Interventions: Device: 1 Day Acuvue Moist | Intervention Type: DEVICE; Name: 1 Day Acuvue Moist; Assigned to Arm(s): Test lens A, Test lens C
C: Arm Label: single-vision glasses and ortho-k lenses; Type: EXPERIMENTAL; Interventions: Device: ortho-k lenses, Device: single-vision glasses | Arm Label: ortho-k lenses; Type: ACTIVE_COMPARATOR; Interventions: Device: ortho-k lenses | Arm Label: single-vision glasses; Type: OTHER; Interventions: Device: single-vision glasses | Intervention Type: DEVICE; Name: ortho-k lenses; Assigned to Arm(s): ortho-k lenses, single-vision glasses and ortho-k lenses | Intervention Type: DEVICE; Name: single-vision glasses; Assigned to Arm(s): single-vision glasses, single-vision glasses and ortho-k lenses
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Outdoor activity; Type: EXPERIMENTAL; Interventions: Behavioral: Outdoor activity | Intervention Type: BEHAVIORAL; Name: Outdoor activity; Assigned to Arm(s): Outdoor activity

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer.
Brief Summary: The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.


Options:
A: Arm Label: Bicalutamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): Bicalutamide
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bicalutamide | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double-Blind Comparative Trial of Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer.
Brief Summary: The purpose of this trial is to study the effect - in terms of time to progression and overall survival - of 2 years of adjuvant bicalutamide 150mg monotherapy, versus placebo, in subjects with histologically or cytologically confirmed non-metastatic adenocarcinoma of the prostate gland.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bicalutamide | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: antiandrogen therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: releasing hormone agonist therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: orchiectomy; Assigned to Arm(s): N/A
C: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A
D: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bicalutamide | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Randomised, Double-blind, Fixed-dose, Bifeprunox Study Combining a 12-Week Placebo-controlled, Quetiapine-referenced Phase With a 12-month Quetiapine-controlled Phase in Patients With Schizophrenia
Brief Summary: The primary purpose of the study is to evaluate the efficacy of bifeprunox in the maintenance phase of schizophrenia compared to placebo.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: risperidone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: risperidone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: risperidone | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): 1, 2, 3
B: Arm Label: Aripiprazole depot; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot | Arm Label: Placebo depot; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo depot | Intervention Type: DRUG; Name: Aripiprazole depot; Assigned to Arm(s): Aripiprazole depot | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Placebo depot
C: Arm Label: Bifeprunox; Type: EXPERIMENTAL; Interventions: Drug: Bifeprunox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine | Intervention Type: DRUG; Name: Bifeprunox; Assigned to Arm(s): Bifeprunox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Quetiapine
D: Arm Label: Bifeprunox; Type: EXPERIMENTAL; Interventions: Drug: Bifeprunox | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Quetiapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Quetiapine | Intervention Type: DRUG; Name: Bifeprunox; Assigned to Arm(s): Bifeprunox | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Quetiapine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Controlled, Superiority Evaluation of Fibrin Patch as an Adjunct to Control Soft Tissue Bleeding During Abdominal, Retroperitoneal, Pelvic, and Thoracic Surgery
Brief Summary: The effectiveness objective of this study is to evaluate whether Fibrin Patch is superior to SURGICEL™ as an adjunct to achieving hemostasis during surgical procedures involving soft tissue bleeding in abdominal, pelvic, retroperitoneal and (non-cardiac) thoracic surgery.


Options:
A: Arm Label: Adrenaline; Type: EXPERIMENTAL; Interventions: Drug: Adrenaline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adrenaline; Assigned to Arm(s): Adrenaline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fibrin Pad | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: SURGICEL™ | Intervention Type: DRUG; Name: Fibrin Pad; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: SURGICEL™; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
D: Arm Label: Tranexamic Acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic Acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Injection

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open Label Study of the Safety and Efficacy of a Topical Gentamicin Collagen Sponge Combined With An Antibiotic Compared to Antibiotic Therapy Alone in Diabetic Patients With Moderately Infected Foot Ulcers
Brief Summary: The purpose of this study is to determine whether the gentamicin-collagen sponge when combined with standard daily wound care and an oral antibiotic (levofloxacin) is safe and effective in treating moderately infected skin ulcers compared to treatment only with standard daily wound care and an oral antibiotic (levofloxacin).


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: gentamicin-collagen sponge and levofloxacin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levofloxacin only | Intervention Type: DRUG; Name: gentamicin-collagen sponge and levofloxacin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Levofloxacin only; Assigned to Arm(s): B
B: Arm Label: ofloxacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: ofloxacin | Arm Label: MSI-78; Type: ACTIVE_COMPARATOR; Interventions: Drug: MSI-78 | Intervention Type: DRUG; Name: ofloxacin; Assigned to Arm(s): ofloxacin | Intervention Type: DRUG; Name: MSI-78; Assigned to Arm(s): MSI-78
C: Arm Label: Patients undergoing medical treatment; Type: OTHER; Interventions: Drug: Ciprofloxacin, Drug: Amoxicillin-Potassium Clavulanate Combination, Drug: Sulfamethoxazole trimethoprim | Arm Label: Patients undergoing surgical treatment; Type: OTHER; Interventions: Procedure: Conservative surgery | Intervention Type: PROCEDURE; Name: Conservative surgery; Assigned to Arm(s): Patients undergoing surgical treatment | Intervention Type: DRUG; Name: Ciprofloxacin; Assigned to Arm(s): Patients undergoing medical treatment | Intervention Type: DRUG; Name: Amoxicillin-Potassium Clavulanate Combination; Assigned to Arm(s): Patients undergoing medical treatment | Intervention Type: DRUG; Name: Sulfamethoxazole trimethoprim; Assigned to Arm(s): Patients undergoing medical treatment
D: Arm Label: ofloxacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: ofloxacin | Arm Label: MSI-78; Type: ACTIVE_COMPARATOR; Interventions: Drug: MSI-78 | Intervention Type: DRUG; Name: ofloxacin; Assigned to Arm(s): ofloxacin | Intervention Type: DRUG; Name: MSI-78; Assigned to Arm(s): MSI-78

Answer: A